NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Even though the results are hopefully very clear by now, there is clearly a tension between unblinding asap and letting the trial run as long as possible to maximize demonstration of OS effect, and possibly even mPFS.

Some may want to think about the medians as they apply to the sub groups as well - for both PFS and OS.

Let's say they are seeing impressive medians in both endpoints for the mesenchymal subgroup - and that group may range between 30 to 50% of these patients (no small number).

But what if there are also other sub groups - that are not currently demonstrating as high a median - and that may be found in the 100 still alive - as well as in the 83 that had not even evented by February 2017...

... and by waiting just a bit longer, the endpoint medians for those subgroups are also raised?